Literature DB >> 25561334

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

William F Penwell1, Adam B Shapiro1, Robert A Giacobbe1, Rong-Fang Gu1, Ning Gao1, Jason Thresher1, Robert E McLaughlin1, Michael D Huband1, Boudewijn L M DeJonge1, David E Ehmann1, Alita A Miller2.   

Abstract

Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii. The clinical use of sulbactam for A. baumannii infections is of interest due to increasing multidrug resistance in this pathogen. However, the molecular drivers of its antibacterial activity and resistance determinants have yet to be precisely defined. Here we show that the antibacterial activities of sulbactam vary widely across contemporary A. baumannii clinical isolates and are mediated through inhibition of the penicillin-binding proteins (PBPs) PBP1 and PBP3, with very low frequency of resistance; the rare pbp3 mutants with high levels of resistance to sulbactam are attenuated in fitness. These results support further investigation of the potential clinical utility of sulbactam.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25561334      PMCID: PMC4325763          DOI: 10.1128/AAC.04808-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

Review 1.  Acinetobacter infection--an emerging threat to human health.

Authors:  Paolo Visca; Harald Seifert; Kevin J Towner
Journal:  IUBMB Life       Date:  2011-10-18       Impact factor: 3.885

Review 2.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.

Authors:  P Poulikakos; G S Tansarli; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-16       Impact factor: 3.267

3.  Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic Management.

Authors:  Harmanjit Singh; Pugazhenthan Thangaraj; Amitava Chakrabarti
Journal:  J Clin Diagn Res       Date:  2013-11-10

Review 4.  Acinetobacter in modern warfare.

Authors:  M K O'Shea
Journal:  Int J Antimicrob Agents       Date:  2012-03-28       Impact factor: 5.283

5.  Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection.

Authors:  Yi-Tzu Lee; Shu-Chen Kuo; Su-Pen Yang; Yi-Tsung Lin; Fan-Chen Tseng; Te-Li Chen; Chang-Phone Fung
Journal:  Clin Infect Dis       Date:  2012-04-11       Impact factor: 9.079

6.  Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii.

Authors:  Felipe Fernández-Cuenca; Luis Martínez-Martínez; Maria Carmen Conejo; Juan A Ayala; Evelio J Perea; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  M V Hayes; D C Orr
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

Review 8.  Sulbactam: a beta-lactamase inhibitor.

Authors:  J K Noguchi; M A Gill
Journal:  Clin Pharm       Date:  1988-01

9.  Fluorescence anisotropy-based measurement of Pseudomonas aeruginosa penicillin-binding protein 2 transpeptidase inhibitor acylation rate constants.

Authors:  Adam B Shapiro; Ning Gao; Rong-Fang Gu; Jason Thresher
Journal:  Anal Biochem       Date:  2014-06-16       Impact factor: 3.365

10.  Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.

Authors:  Anna S Levin; Carlos E Levy; A Edison I Manrique; Eduardo A S Medeiros; Silvia F Costa
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

View more
  55 in total

1.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.

Authors:  Yunxing Yang; Qingye Xu; Tingting Li; Ying Fu; Yue Shi; Peng Lan; Dongdong Zhao; Qiong Chen; Zhihui Zhou; Yan Jiang; Anton Y Peleg; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

4.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

5.  Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

Authors:  Sarah M McLeod; Adam B Shapiro; Samir H Moussa; Michele Johnstone; Robert E McLaughlin; Boudewijn L M de Jonge; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

8.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

9.  Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  S Mohd Sazlly Lim; A J Heffernan; J A Roberts; F B Sime
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

10.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.